NCT02974725 2025-04-13A Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaNovartisPhase 1 Terminated241 enrolled
NCT02900664 2022-03-29A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)NovartisPhase 1 Completed283 enrolled